An Open-label Extension Study to Assess the Long-term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia
Latest Information Update: 12 May 2025
At a glance
- Drugs Trospium chloride/xanomeline (Primary)
- Indications Schizophrenia
- Focus Adverse reactions
- Acronyms ARISE-2
- Sponsors Karuna Therapeutics
Most Recent Events
- 04 May 2025 Planned End Date changed from 16 Mar 2026 to 19 Mar 2026.
- 04 May 2025 Planned primary completion date changed from 16 Mar 2026 to 19 Mar 2026.
- 28 Jan 2025 Planned End Date changed from 27 Feb 2026 to 16 Mar 2026.